中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

93 records (took 0.025 seconds)

    ADAPTATION OF AUTOMATIC INSULIN DELIVERY (AID) FOR USERS WITH BASAL TO BOLUS MISMATCH
    6.
    发明申请
    ADAPTATION OF AUTOMATIC INSULIN DELIVERY (AID) FOR USERS WITH BASAL TO BOLUS MISMATCH 有权

    公开(公告)号：US20220280721A1

    公开(公告)日：2022-09-08

    申请号：US17684652

    申请日：2022-03-02

    Applicant: Insulet Corporation

    Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

    IPC: A61M5/172 ,  G16H20/17

    Abstract: Exemplary embodiments provide more customized basal insulin amounts for users to better regulate blood glucose (BG) concentration levels. The exemplary embodiments do not statically assume that the daily basal amount for each user is 50% of TDI. Instead, actual TDI data may be gathered for each user and may be used to adjust the TDI value for that user to an updated value. In addition, the ratio of basal to TDI may be adjusted for the user based on the actual ratio determined from data gathered over one or more days. As a result, better BG concentration level control may be realized.

    DRUG DELIVERY DEVICE INCLUDING PUMP WITH FLOATING MICRONEEDLE ASSEMBLY
    7.
    发明申请
    DRUG DELIVERY DEVICE INCLUDING PUMP WITH FLOATING MICRONEEDLE ASSEMBLY 有权

    公开(公告)号：US20220273927A1

    公开(公告)日：2022-09-01

    申请号：US17669106

    申请日：2022-02-10

    Applicant: Insulet Corporation

    Inventor： Maureen MCCAFFREY ,  Steven CARDINALI ,  Jason O'CONNOR

    IPC: A61M37/00 ,  A61M5/142

    Abstract: Embodiments of the present disclosure relate to techniques, processes, devices or systems including a floating microneedle assembly decoupled from the device and protected by a pump housing. In one approach, a wearable drug delivery device may include a pump housing including a base attachable to a user, and a microneedle assembly coupled to a cannula. The microneedle assembly may be operable to deliver a liquid drug to the user, wherein the microneedle assembly comprises a carrier positioned proximate an opening of the base, and wherein the carrier comprises a plurality of microneedles operable to extend through the opening of the base to penetrate a skin of the user.

    WEARABLE MICRO-DOSING DRUG DELIVERY DEVICE
    8.
    发明申请
    WEARABLE MICRO-DOSING DRUG DELIVERY DEVICE 有权

    公开(公告)号：US20220062536A1

    公开(公告)日：2022-03-03

    申请号：US17412729

    申请日：2021-08-26

    Applicant: Insulet Corporation

    Inventor： Jason O'CONNOR ,  Matthew ALLES ,  Robert SANZONE ,  Craig BRODEUR ,  Joseph MELO ,  Christopher WILLIAMS ,  Noel SCHAEFFER

    IPC: A61M5/142

    Abstract: The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.

    USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM
    10.
    发明申请
    USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM 有权

    公开(公告)号：US20210244881A1

    公开(公告)日：2021-08-12

    申请号：US16789051

    申请日：2020-02-12

    Applicant: Insulet Corporation

    Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

    IPC: A61M5/172 ,  A61K38/28 ,  A61M31/00 ,  G16H40/63

    Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

Patent Agency Ranking